Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158402 | 0.91 | CYP2C9 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3854890 | 0.90 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3854418 | 0.90 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13307503 | 0.86 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3853929 | 0.86 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3854290 | 0.85 | CYP2C19 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3859499 | 0.85 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL475420 | 0.84 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5176018 | 0.84 | CYP2C9 (0.37) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5188070 | 0.83 | CYP2C19 (0.42) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-7585885-B2 | Pyrrolidine derivatives useful as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1740575-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005108358-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | CA12 330/4885CA1 63/4885CA2 497/4885 |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | BACE1, BACE2, PSEN1 | CA12 2516/4885CA1 324/4885CA2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.